INS and chronic kidney disease: In the phase 1 study, patients who returned for evaluation were older, had longer disease duration, had greater frequency of a history of cardiovascular disease or chronic kidney disease, had higher medication receipt (with the exception of insulin), and had higher target attainment at baseline compared with patients who did not return for evaluation (eTable 2 in Supplement 2).